{
    "clinical_study": {
        "@rank": "33278", 
        "arm_group": {
            "arm_group_label": "BEMA Buprenorphine NX films", 
            "arm_group_type": "Experimental", 
            "description": "BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone)will be provided in 3.361 and 5.447 cm2 film sizes, respectively."
        }, 
        "brief_summary": {
            "textblock": "This is an open label study in opioid dependent subjects maintained on a stabilized dose of\n      Suboxone tablets or films.  The purpose is to assess the safety and tolerability of BEMA\n      Buprenorphine NX administered once daily for 12 weeks to opioid dependent subjects\n      stabilized on Suboxone (buprenorphine/naloxone) tablets or films.\n\n      Eligible subjects will be converted to an approximately equal dose of BEMA Buprenorphine NX.\n       This dose will be taken throughout the 12-week treatment period with dose adjustments as\n      clinically indicated for either the control of opioid dependence or adverse events (AEs)."
        }, 
        "brief_title": "An Open Label Study To Assess The Safety And Tolerability Of BEMA\u00ae Buprenorphine NX In Opioid Dependent Subjects", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Opioid Dependence", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "This is an open label study in opioid dependent subjects maintained on a stabilized dose of\n      Suboxone tablets or films.\n\n      Eligible subjects will be converted to an approximately equal dose of BEMA Buprenorphine NX.\n       This dose will be taken throughout the 12-week treatment period with dose adjustments as\n      clinically indicated for either the control of opioid dependence or adverse events (AEs).\n      Subjects will be monitored for evidence of buccal irritation attributed to the application\n      of the BEMA Buprenorphine NX film and opioid dependence control according to the Clinical\n      Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction - A Treatment\n      Improvement Protocol (TIP 40) guidelines for the use of buprenorphine in the management of\n      opioid dependence.\n\n      The total duration of participation for each subject will be up to approximately 18 weeks\n      and includes a Screening period (subjects continue to take Suboxone tablets or films),\n      Baseline visit, a 12-week open label treatment period (subjects take BEMA Buprenorphine NX\n      films and at the Day 84 visit, subjects will return to their prior Suboxone treatment), and\n      a Follow-up Visit.\n\n      Vital signs, pulse oximetry, opioid withdrawal symptoms, adverse events (AEs), oral\n      examinations, and concomitant medications will be assessed at intervals throughout the\n      study. Clinical laboratory assessments, urine toxicology and buprenorphine testing, and\n      12-lead electrocardiograms (ECGs) will also be performed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent obtained at Screening, prior to any study procedure being\n             performed\n\n          2. Male or non-pregnant and non-nursing female. A female of childbearing potential is\n             eligible to participate in this study if she is not pregnant, and is using an\n             acceptable method of birth control\n\n          3. Subject is aged 18 to 65 years of age, inclusive\n\n          4. Diagnosis of opioid dependence per the Diagnostic and Statistical Manual of Mental\n             Disorders - 4th edition (text revision) (DSM-IV-TR) criteria in the past 12 months\n             including physical dependence on opioids and addiction with compulsive use despite\n             harm\n\n          5. Currently taking a stable, single daily dose of 16/4 to 32/8 mg Suboxone tablets or\n             films (buprenorphine/naloxone) for at least 30 days\n\n          6. Subject is in good general health; with no clinically significant findings on medical\n             history, physical examination, safety laboratory test and ECG in the judgment of the\n             investigator at screening. Serum creatinine, alanine aminotransferase (ALT), and\n             aspartate aminotransferase (AST) values must be within 3-times the upper limit of\n             normal (ULN). Pulse oximetry must be \u226596%, systolic blood pressure \u2265110 mmHg, and\n             diastolic blood pressure \u226565 mmHg.\n\n        Exclusion Criteria:\n\n          1. Hypokalemia, hypomagnesemia, or clinically unstable cardiac disease, including:\n             unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart\n             failure, active myocardial ischemia, or clinically significant arrhythmias\n\n          2. History of Long QT Syndrome, or an immediate family member with this condition\n\n          3. Currently taking Class IA antiarrhythmic medications (eg, quinidine, procainamide,\n             disopyramide) or Class III antiarrhythmic medications (eg, sotalol, amiodarone,\n             dofetilide)\n\n          4. Uncontrolled hypertension defined as systolic blood pressure >170 mmHg and diastolic\n             blood pressure >90 mmHg at Baseline\n\n          5. Pulse oximetry \u226493% at Baseline, regardless of cause\n\n          6. Clinically significant abnormality on 12-lead ECG, including a QTc interval >490\n             milliseconds\n\n          7. Use of any medication, nutraceutical or herbal product with CYP3A4 inhibition or\n             induction properties within the past 30 days (see Appendix 4 for a list of applicable\n             drugs). This exclusion also extends to grapefruit juice and grapefruit\n             juice-containing products as well as St. John's wort and St. John's wort-containing\n             products (prescription or nonprescription drugs, vitamins, minerals, or\n             dietary/herbal supplements).\n\n          8. Diagnosis of moderate to severe hepatic impairment\n\n          9. Use of an investigational drug or device within the last 30 days\n\n         10. Participation in a previous clinical study of BEMA Buprenorphine NX or BEMA\n             Buprenorphine\n\n         11. History of hypersensitivity, allergy, or intolerance to buprenorphine, naloxone, or\n             related drugs\n\n         12. Pierced tongue or mouth\n\n         13. Any clinically significant abnormality of the buccal mucosa which could impact drug\n             absorption\n\n         14. Suicidal risk, as determined by meeting any of the following:\n\n               1. History of suicidal ideation \u2264 3 months prior to Baseline with a score of 4\n                  (intent to act) or 5 (specific plan and intent) on the eC-SSRS\n\n               2. History of suicidal behavior \u2264 1 year prior to Baseline (actual attempt,\n                  interrupted attempt, aborted attempt and/or preparatory acts/behavior) on the\n                  eC-SSRS\n\n         15. A history or current evidence of any clinically significant disorder or any other\n             condition which in the opinion of the investigator, would jeopardize the safety of\n             the subject or impact the validity of the study results"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "249", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666119", 
            "org_study_id": "BNX-201"
        }, 
        "intervention": {
            "arm_group_label": "BEMA Buprenorphine NX films", 
            "description": "BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.", 
            "intervention_name": "BEMA Buprenorphine NX films", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Opioid dependence", 
            "Suboxone", 
            "addiction", 
            "BEMA Buprenorphine NX", 
            "oral transmucosal"
        ], 
        "lastchanged_date": "July 26, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35215"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haleyville", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35565"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32256"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maitland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32751"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "North Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33161"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prairie Village", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66206"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fall River", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02720"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belvidere", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07823"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84106"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Study To Assess The Safety And Tolerability Of BEMA\u00ae Buprenorphine NX In Opioid Dependent Subjects (BNX-201)", 
        "overall_official": {
            "affiliation": "Parkway Medical", 
            "last_name": "Greg Sullivan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The following will be assessed:\nAEs\nOral examination\nPeriodic physical examinations\nVital signs and pulse oximetry\nECG\nPeriodic clinical laboratory evaluations including hematology, blood chemistry and urinalysis\nSuicidality assessments", 
            "measure": "Assess the safety and tolerability of BEMA Buprenorphine NX administered once daily for 12 weeks to opioid dependent subjects stabilized on Suboxone (buprenorphine/naloxone) tablets or films", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666119"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Eligible subjects stabilized on Suboxone maintenance therapy (8-32 mg/day) will be enrolled and switched to an equivalent dose using 3.5/0.6 mg and 5.25/0.9 mg BEMA Buprenorphine NX.\nAt each visit, adverse events (AEs), including behavioral events, will be assessed; oral examinations will be performed to assess local irritation (monthly); and urine samples will be collected and analyzed for opioids of abuse, buprenorphine, and intermittent pregnancy testing.", 
            "measure": "Determine the most appropriate conversion ratio for opioid dependent subjects treated with Suboxone tablets or films to BEMA Buprenorphine NX", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "BioDelivery Sciences International", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioDelivery Sciences International", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}